EMA Authorised: Lantus (insulin glargine) — sanofi-aventis Deutschland GmbH

View source ↗

Summary

The EMA authorised Lantus (insulin glargine) by sanofi-aventis Deutschland GmbH for diabetes mellitus; decision date 05/03/2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: sanofi-aventis Deutschland GmbH. Decision date: 05/03/2026